DiaMedica Therapeutics Inc. (DMAC)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 2.5800 |
| Open | 2.5800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.5010 - 2.6250 |
| 52 Week Range | 1.5800 - 4.7500 |
| Volume | |
| Avg. Volume | 37,572 |
| Market Cap | 98.311M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6000 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
Simply Wall St.Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
Multiple insiders secured a larger position in DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) shares over the last 12...
ZacksDiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
Business WireDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
MINNEAPOLIS, April 17, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
© 2024 Yahoo. All rights reserved.